Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer
Name	Society for Immunotherapy of Cancer
Abbreviation	SITC
Formation	1984
Type	Professional association
Headquarters	Milwaukee, Wisconsin
Region served	International
Fields	Immunotherapy, Oncology, Immunology

Society for Immunotherapy of Cancer is a professional association focused on advancing cancer immunotherapy through research, clinical practice, education, and policy. The organization engages clinicians, scientists, regulators, and industry stakeholders to accelerate translation of discoveries into therapies for melanoma, non-small-cell lung carcinoma, hematologic malignancy, and other oncology indications. It convenes annual meetings, issues clinical guidelines, and partners with regulatory agencies and foundations to shape standards in biotechnology and pharmaceutical development.

History

The organization traces roots to early meetings among researchers working on tumor immunology, monoclonal antibody development, and cytokine biology in the 1970s and 1980s alongside institutions such as the National Institutes of Health, Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute. Milestones include coordination with regulatory milestones like approvals by the Food and Drug Administration for checkpoint inhibitors and the emergence of CAR T-cell therapy validated at centers including University of Pennsylvania and Stanford University. Leadership has included physician-scientists affiliated with Johns Hopkins Hospital, Massachusetts General Hospital, UCLA, and international partners at Institut Pasteur and Karolinska Institutet.

Mission and Activities

The society's mission aligns with global efforts in World Health Organization initiatives, collaborations with research funders such as the National Cancer Institute, and engagement with philanthropic organizations like the American Cancer Society and the Bill & Melinda Gates Foundation. Activities encompass fostering basic research in T cell biology, promoting translational trials at academic centers such as Mayo Clinic and Cleveland Clinic, and supporting regulatory science dialogues with agencies including the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency. Programs span consensus guideline development, patient-centered initiatives linked to foundations like Stand Up To Cancer, and data-sharing frameworks with consortia such as the Cancer Immunome Atlas.

Membership and Governance

Membership comprises clinicians, researchers, trainees, and industry representatives drawn from institutions including Johns Hopkins University, University of California, San Francisco, Yale University, Cold Spring Harbor Laboratory, Salk Institute, Imperial College London, University College London, and University of Toronto. Governance includes an elected board of directors, committees featuring leaders from American Society of Clinical Oncology, European Society for Medical Oncology, and advisory councils with participation from regulatory and payer representatives such as Centers for Medicare & Medicaid Services and international health ministries. Honorary members have originated from awardees of prizes such as the Lasker Award and the Nobel Prize in Physiology or Medicine.

Scientific Programs and Meetings

The society organizes an annual meeting comparable in scope to conferences hosted by American Association for Cancer Research, American Society of Clinical Oncology, and European Cancer Congress. Scientific programs highlight plenary sessions, symposia, and poster tracks featuring work from investigators at Harvard Medical School, Columbia University, University of Oxford, University of Cambridge, Princeton University, Massachusetts Institute of Technology, and international research hubs in Tokyo, Beijing, Seoul, and Geneva. Workshops address translational topics including biomarker development aligned with projects at Broad Institute, clinical trial design practiced at MD Anderson Cancer Center, and manufacturing scale-up discussed with partners like Genentech, Roche, Novartis, and Bristol Myers Squibb.

Publications and Guidelines

The society produces clinical practice guidelines and consensus statements used by clinicians at institutions including Mount Sinai School of Medicine and University of Michigan Health System. Publications appear in peer-reviewed journals alongside contributions from editors affiliated with Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology, and Cancer Research. Guideline topics cover immune-related adverse events, response criteria inspired by work from RECIST investigators, and standards for cell therapy manufacturing compatible with Good Manufacturing Practice frameworks and discussions with International Council for Harmonisation.

Education, Training, and Certification

Educational offerings include online curricula, workshops, and certification paths for practitioners from residency and fellowship programs at UCSF Medical Center, Stanford Health Care, and Brigham and Women’s Hospital. Training emphasizes competencies in administering checkpoint inhibitors, managing immune-related adverse events using protocols influenced by experts at Peter MacCallum Cancer Centre, and conducting early-phase trials modeled on programs at Fred Hutch. Mentorship and career development initiatives engage trainees from graduate programs at University of Washington, postdoctoral researchers from Salk Institute, and clinician-scientists supported by career awards from Howard Hughes Medical Institute and national research councils.

Partnerships and Advocacy

The society partners with advocacy organizations such as American Association for Cancer Research, American Society of Hematology, Lymphoma Research Foundation, Alberta Health Services, and international consortia including Translational Research in Oncology. It advocates for research funding with bodies like the European Commission, clinical trial access aligned with ClinicalTrials.gov registries, and policy dialogues with payers including National Health Service (England). Collaborative initiatives span public-private consortia with biopharma companies, collaborations with foundations like Susan G. Komen for the Cure, and global outreach in partnership with Union for International Cancer Control.

Category:Medical societies Category:Cancer organizations Category:Immunology organizations